Update of the therapeutics of Inflammatory Bowel Disease (IBD). Biological and biosimilar treatments. Second part.

Abstract

Inflammatory Bowel Disease mainly combines Crohn's Disease and Ulcerative Colitis. These pathologies chronically affect the digestive system and their incidence continues to grow worldwide. Within the immense range of therapeutic options available for its treatment, biological and biosimilar drugs have positioned themselves as one of the most widely used in the last 30 years. Biological drugs are aimed at slowing down the inflammatory process and do so by acting on tumor necrosis factors, occupying the integrin receptors, or blocking some cytokines. Biosimilars are substances equivalent to these, but not identical, for a much affordable cost.